CD8A and neoplasm: In addition, a neoantigen vaccine (NeoVAC) coupled with anti-PD-1 induced robust anti-tumor responses and persistent tumor-specific immune memory in HCC by enhancing CD8+ Trm infiltration, making it a potential immunotherapy target in HCC [85].